查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012930

良性前列腺增生治疗市场：2026-2032年全球市场预测（依治疗方法、产品类型、最终用户和通路划分）

Benign Prostatic Hyperplasia Treatment Market by Treatment Type, Product Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

良性摄护腺增生 (BPH) 治疗市场预计到 2025 年将达到 92 亿美元，到 2026 年将成长到 97.4 亿美元，到 2032 年将达到 139.6 亿美元，年复合成长率为 6.12%。

主要市场统计数据
基准年 2025 92亿美元
预计年份：2026年 97.4亿美元
预测年份 2032 139.6亿美元
复合年增长率 (%) 6.12%

探索新的临床进展和市场驱动因素，这些进展和因素将定义良性前列腺增生治疗的下一个范式。

良性前列腺增生（BPH）因其在老年男性族群中的高发病率及其对生活品质（QOL）的显着影响，已成为重要的临床关注领域。随着人口结构向老龄化患者的转变加速，全球医疗保健系统面临越来越大的压力，需要提供安全、有效且经济的治疗方案。近年来，临床创新、患者偏好和不断变化的医疗保险报销机制之间的相互作用，在一定程度上重新定义了与BPH相关的中重度下泌尿道症状的治疗目标。

确定将重塑良性前列腺增生症治疗方法和患者疗效的根本技术和监管变革。

良性前列腺增生（BPH）的治疗格局正在经历一场翻天覆地的变革，这主要得益于技术突破和监管环境的变化。传统的治疗方法主要依赖药物治疗和经尿道前列腺切除术，而如今，我们正见证着尖端能量治疗方法、影像引导介入治疗和标靶栓塞术的涌现。这些创新旨在最大限度地减少手术相关併发症，同时尽可能保留患者的泌尿和性功能，这正是当今患者群体最关注的问题。

分析美国关税调整对良性前列腺增生症治疗的可近性、供应链和创新途径的综合影响。

美国宣布的2025年关税调整正在对全球供应链产生连锁反应，影响良性前列腺增生（BPH）治疗关键组件的成本结构和供应。许多医疗设备，从导管和电切镜到泌尿系统雷射和植入，都源自海外或包含海外製造的组件。随着进口关税的提高，经销商和医疗服务提供者面临采购成本增加的困境，这影响了价格谈判和报销协商。

深入了解良性前列腺增生 (BPH) 的治疗类型、产品类型、最终用户和分销管道的详细细分，从而影响其管理方法。

对市场区隔的深入理解揭示了策略投资和产品开发的关键转折点。考虑到治疗方法方案，药物治疗仍然至关重要，其中5α还原酶抑制剂和α阻断剂是首选治疗方案。然而，微创治疗，包括前列腺动脉栓塞术和蒸气疗法，由于恢復时间短、安全性高，正迅速普及。同时，外科治疗也不再局限于传统的经经尿道前列腺切除术，而是扩展到雷射手术、前列腺尿道提升术和经尿道切开术等，所有这些手术都以最大程度减少组织损伤为目标。

评估北美、欧洲、中东和非洲以及亚太地区市场趋势的区域差异，并为良性前列腺增生 (BPH) 的标靶治疗策略做出贡献。

区域趋势在良性前列腺增生症的治疗生态系统中发挥着至关重要的作用，每个地区都有其独特的监管、临床和经济考量。在美洲，健全的医保报销体系和技术的早期应用，以及广泛的临床试验网络和成熟的支付方-医疗服务提供方合作关係，正在推动基于医疗设备的治疗方法和先进药物疗法的快速普及。

本报告重点介绍了良性前列腺增生 (BPH) 治疗领域领先的生物製药、医疗设备和技术公司的创新策略、伙伴关係和竞争趋势。

良性前列腺增生（BPH）领域的竞争格局呈现出老牌製药公司和创新医疗设备製造商并存的局面。大型製药企业凭藉其在5α-还原酶抑制剂和α阻断剂领域数十年的产品系列经验，占据市场主导地位；而相关的生物製药公司则致力于探索能够同时缓解症状和促进组织重塑的新型联合治疗。

制定切实可行的策略建议，以提高良性前列腺增生治疗的临床疗效、市场渗透率和患者接受度。

具有前瞻性的产业领导者应优先考虑采取多管齐下的策略，以在不断发展的良性前列腺增生市场中保持竞争优势。首先，投资下一代微创技术，特别是那些适用于门诊和诊所环境的技术，将满足患者对缩短復原时间和提高生活品质的需求。与关键意见领袖 (KOL) 和病例较多的医疗机构合作开展试验计画，可以加快技术推广应用，并产生令人信服的真实世界证据，从而支持医保报销谈判。

为确保良性前列腺增生市场评估研究结果的可靠性，详细阐述了严格的资料收集、分析和检验协议。

本研究采用严谨的调查方法，结合了全面的二手资料研究、针对性的一手访谈和资料三角验证。首先，我们系统地分析了同行评审期刊、监管资料库、专利申请和行业白皮书，以建立治疗方法、医疗设备创新和政策趋势的可靠基准。我们整理了以往的监管核准和指南修订情况，以确定关键市场变化的时机和范围。

本研究整合了关键发现和策略意义，以确定良性前列腺增生治疗领域未来的方向和机会。

主要研究结果总结表明，市场正经历重大变革。微创疗法的进步、监管路径的协调统一以及关税趋势带来的供应链考量日益增加，正在重塑治疗流程和竞争动态。细分市场分析凸显了非手术干预和专科产品类型的重要性日益增长，而区域洞察则强调了在美洲、欧洲、中东和非洲以及亚太地区製定量身定制的打入市场策略的必要性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 良性摄护腺增生治疗市场（依治疗方法划分）

  • 药物治疗
    • 5α-还原酶抑制剂
    • α受体阻断剂
  • 微创治疗
    • 摄护腺动脉栓塞术
    • 蒸气疗法
  • 手术治疗
    • 雷射手术
    • 摄护腺尿道拉提手术
    • 经尿道前列腺切开术
    • 经尿道前列腺切除术

第九章 良性摄护腺增生治疗市场：依产品类型划分

  • 导管
  • 电极
  • 植入
  • 摄护腺支架
  • 电切镜
  • 泌尿系统雷射

第十章 良性摄护腺增生治疗市场：依最终使用者划分

  • 门诊手术中心
  • 诊所
  • 居家照护
  • 医院

第十一章 良性摄护腺增生治疗市场：依通路划分

  • 离线
  • 在线的

第十二章 良性摄护腺增生治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 良性摄护腺增生治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 良性摄护腺增生治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国良性摄护腺增生治疗市场

第十六章：中国良性摄护腺增生治疗市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alembic Pharmaceuticals Limited
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Coloplast Group
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Endo International PLC
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals PLC
  • IPG Photonics Corporation
  • Lumenis Ltd.
  • Olympus Corporation
  • Organon group of companies
  • PROCEPT BioRobotics Corporation
  • ProstaLund AB
  • Quanta System
  • Richard Wolf GmbH
  • Teleflex Incorporated
  • Urologix, LLC.
Product Code: MRR-437D4595848A

The Benign Prostatic Hyperplasia Treatment Market was valued at USD 9.20 billion in 2025 and is projected to grow to USD 9.74 billion in 2026, with a CAGR of 6.12%, reaching USD 13.96 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.20 billion
Estimated Year [2026] USD 9.74 billion
Forecast Year [2032] USD 13.96 billion
CAGR (%) 6.12%

Exploring the Emerging Clinical Developments and Market Drivers Defining the Next Generation of Benign Prostatic Hyperplasia Treatment Paradigms

Benign prostatic hyperplasia (BPH) has emerged as a critical area of clinical focus due to its high prevalence among aging male populations and its profound impact on quality of life. As the demographic shift towards an older patient base accelerates, healthcare systems worldwide face mounting pressure to deliver safe, effective, and cost-efficient interventions. In recent years, the interplay of clinical innovation, patient preference, and evolving reimbursement pathways has partially redefined treatment objectives for moderate to severe lower urinary tract symptoms associated with prostatic enlargement.

The clinical pipeline now features an expanding array of pharmacotherapies aimed at both symptom relief and underlying disease modification. Novel agents targeting androgen pathways, inflammatory mediators, and smooth muscle tone within the prostate are under active investigation. Concurrently, minimally invasive technologies have transitioned from niche options to mainstream considerations, offering shorter recovery times and preserved sexual function relative to traditional surgical approaches. Moreover, professional guidelines have begun to integrate these advancements, urging a more personalized treatment algorithm based on symptom severity, prostate volume, and patient comorbidities.

Consequently, stakeholders across the public and private sectors are aligning around a paradigm that balances clinical efficacy with patient-centric factors such as procedure durability, side effect profiles, and access to care. This introduction sets the stage for an in-depth exploration of how recent clinical developments and market drivers converge to define the next generation of BPH treatment paradigms.

Identifying the Fundamental Technological and Regulatory Transformations Reshaping Treatment Modalities and Patient Outcomes in Prostatic Enlargement Management

The landscape of benign prostatic hyperplasia treatment is undergoing profound transformation driven by both technological breakthroughs and shifting regulatory frameworks. Historically dominated by heavy reliance on pharmacotherapy and transurethral resection surgery, the field now witnesses the rise of cutting-edge energy-based modalities, image-guided interventions, and targeted embolic therapies. These innovations aim to minimize procedural morbidity while preserving urinary and sexual function, key priorities for today's patient cohorts.

On the regulatory front, health authorities have begun to streamline pathways for minimally invasive medical devices and combination regimens, reflecting an increased willingness to consider surrogate endpoints and patient-reported outcomes. Harmonization efforts across major markets are reducing approval timelines for technologies that demonstrate safety and performance in robust clinical studies. Furthermore, the integration of real-world evidence into post-market surveillance has accelerated iterative improvements, enabling manufacturers to refine device designs and procedural techniques at an unprecedented pace.

As a result, treatment modalities once considered experimental are gaining momentum in routine practice. The convergence of technology, regulation, and patient-centered care is reshaping the fundamental approach to prostatic enlargement management. This section delves into these transformative forces, highlighting how they coalesce to create new opportunities for improved patient outcomes and streamlined clinical pathways.

Analyzing the Converging Effects of United States Tariff Adjustments on Treatment Access Supply Chains and Innovation Paths for Prostatic Hyperplasia Care

United States tariff adjustments announced in 2025 have generated ripple effects across global supply chains, impacting the cost structures and accessibility of key benign prostatic hyperplasia treatment components. Many medical devices-ranging from catheters and resectoscopes to urology lasers and implants-originate from or incorporate parts manufactured abroad. As import duties rise, distributors and healthcare providers confront increased procurement expenses, which in turn influence pricing negotiations and reimbursement discussions.

Manufacturers have responded by reassessing their production footprints, exploring near-sourcing strategies, and renegotiating supplier contracts to mitigate steep cost escalations. Simultaneously, emerging trade agreements and tariff exemptions for certain medical goods have provided limited relief, though administrative burdens remain substantial. Consequently, device innovators must balance the imperative to maintain margins with the need to ensure equitable patient access, particularly in outpatient and ambulatory surgical center settings.

Looking ahead, the tariff environment is likely to catalyze broader supply chain resilience measures within the industry. Strategic collaborations and investment in localized manufacturing are expected to gain prominence as companies seek to insulate their operations from future policy shifts. This analysis examines how recent tariff modifications are redefining procurement, distribution, and innovation pathways for prostatic hyperplasia care.

Uncovering Granular Treatment Type Product End User and Distribution Channel Segmentation Insights Shaping Approaches to Prostatic Hyperplasia Management

A nuanced understanding of market segmentation reveals critical inflection points for strategic investment and product development. When treatment type is considered, medications continue to hold foundational importance, with 5-alpha-reductase inhibitors and alpha blockers serving as first-line pharmacologic interventions. Yet the minimally invasive therapy segment, encompassing prostate artery embolization and water vapor therapy, is rapidly gaining traction due to shorter recovery times and favorable safety profiles. At the same time, surgical treatments have diversified beyond traditional transurethral resection of the prostate, now including laser surgery, prostatic urethral lift, and transurethral incision techniques that prioritize minimal tissue disruption.

Examining product type segmentation highlights the essential role of supporting technologies. Catheters, electrodes, and resectoscopes remain indispensable for interventional procedures, while prostatic stents and specialized urology lasers are becoming increasingly sophisticated in their design and application. Each category presents distinct development pathways, driven by evolving clinical requirements and user feedback from surgeons and interventional radiologists.

End-user analysis further clarifies market dynamics, as ambulatory surgical centers gain preference for office-based procedures while hospitals maintain their position in complex surgical cases. Clinics offering pharmacotherapy and minimally invasive office procedures are expanding service portfolios, and homecare models for medication management and post-procedure monitoring are on the rise. Finally, distribution channel trends underscore a transition from traditional hospital procurement networks toward integrated online platforms that streamline ordering, enable real-time inventory management, and support remote training modules for new devices.

Evaluating Geographic Market Variations Across Americas Europe Middle East Africa and Asia Pacific to Inform Targeted Prostatic Hyperplasia Treatment Strategies

Regional dynamics play a pivotal role in shaping the benign prostatic hyperplasia treatment ecosystem, with each geography presenting unique regulatory, clinical, and economic considerations. In the Americas, robust reimbursement frameworks and early technology adoption drive rapid integration of both device-based therapies and advanced pharmacologics, supported by extensive clinical trial networks and established payer-provider collaborations.

In Europe, Middle East & Africa, diverse healthcare infrastructures foster a dual focus on cost containment and equitable access. Regulatory harmonization across the European Union facilitates cross-border device approvals, while emerging markets in the Middle East and Africa prioritize capacity building for minimally invasive techniques, often through international partnerships and training programs.

Across the Asia-Pacific region, accelerating population aging and growing awareness of male health issues are creating a surge in demand for both first-line medications and new procedural options. Governments are increasingly incentivizing local manufacturing and public-private research collaborations to expand access in less penetrated markets. Consequently, regional strategies must be tailored to navigate variations in clinical practice, reimbursement policies, and patient expectations across these diverse territories.

Highlighting Innovative Strategies Partnerships Competitive Dynamics Among Leading Biopharmaceutical Device Technology Companies in Prostatic Hyperplasia Care

Competitive dynamics in the benign prostatic hyperplasia arena are defined by a blend of established pharmaceutical firms and innovative device manufacturers. Leading drug makers leverage decades of portfolio experience in 5-alpha-reductase inhibitors and alpha blockers, while adjacent biopharma players explore novel combination therapies that address both symptom relief and tissue remodeling.

On the device side, global medical technology organizations continue to refine energy-based platforms, offering improved precision and reduced procedural times. Strategic partnerships between device innovators and contract research organizations have accelerated clinical validation, helping to secure favorable regulatory designations. At the same time, emerging companies specialize in niche delivery systems such as water vapor and embolic therapies, carving out competitive positions through targeted clinical data and differentiated user experiences.

The convergence of digital health and urology has also given rise to integrated software solutions that support pre-procedure planning, remote follow-up, and patient-reported outcome tracking. Consequently, the competitive field extends beyond core product offerings to encompass service ecosystems and data analytics capabilities that enhance long-term value for providers and patients alike.

Formulating Actionable Strategic Recommendations to Enhance Clinical Effectiveness Market Penetration and Patient Adoption in Prostatic Hyperplasia Treatment

Forward-looking industry leaders should prioritize a multifaceted approach to maintain competitive advantage in the evolving benign prostatic hyperplasia market. First, investing in next-generation minimally invasive technologies-particularly those with outpatient or office-based application-will address patient demand for reduced recovery times and preserved quality of life. Establishing collaborative pilot programs with key opinion leaders and high-volume centers can accelerate adoption curves and generate compelling real-world evidence to support reimbursement negotiations.

Second, strengthening supply chain resilience through diversified sourcing and near-shoring initiatives will mitigate the financial impacts of evolving trade policies. Engaging in joint ventures with regional manufacturing partners can also facilitate market entry in underpenetrated territories. Third, integrating digital health tools into pre- and post-treatment pathways will enhance patient engagement and enable remote monitoring of outcomes, providing a richer data set for both clinical optimization and payer discussions.

Finally, customizing market access strategies to regional regulatory nuances-such as expedited device review programs in the Americas or harmonized EU approval processes-will streamline time to market. By synchronizing clinical development plans with local policy frameworks and reimbursement landscapes, companies can secure favorable positioning and drive sustainable growth across multiple geographies.

Detailing Rigorous Data Collection Analysis and Validation Protocols Ensuring Robustness of Research Findings in Prostatic Hyperplasia Market Assessment

This research employed a rigorous methodology combining comprehensive secondary research with targeted primary interviews and data triangulation. Initially, peer-reviewed journals, regulatory databases, patent filings, and industry white papers were systematically analyzed to construct a robust baseline of therapeutic modalities, device innovations, and policy developments. Historical regulatory approvals and guideline revisions were mapped to identify timing and scope of major market shifts.

Complementing the desk research, structured interviews with leading urologists, interventional radiologists, procurement specialists, and payers provided firsthand insights into clinical preferences, procedural workflows, and reimbursement challenges. Quantitative data points were validated through cross-referencing publicly available clinical trial registries and device approval summaries, ensuring consistency across multiple sources.

Finally, an iterative review process engaged subject matter experts to refine assumptions, resolve discrepancies, and contextualize findings within broader healthcare trends. This layered approach-incorporating secondary evidence, expert validation, and market feedback-underpins the reliability and depth of the strategic insights presented throughout this report.

Synthesizing Key Findings and Strategic Implications to Illuminate Future Directions and Opportunities in the Benign Prostatic Hyperplasia Treatment Arena

Bringing together the key findings reveals a market at the cusp of significant transition. Advances in minimally invasive therapies, alignment of regulatory pathways, and heightened tariff-driven supply chain considerations are collectively reshaping treatment algorithms and competitive dynamics. Segmentation analysis underscores the growing importance of non-surgical interventions and specialized product categories, while regional insights highlight the need for tailored market access strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific.

The interplay between established pharmaceutical agents and next-generation device platforms points to an integrated future in which combination therapies and digital health solutions drive patient-centered care. For stakeholders eager to navigate this complex ecosystem, the ability to anticipate policy shifts, forge strategic partnerships, and invest in differentiated technologies will determine long-term success. By synthesizing clinical innovation, operational resilience, and market intelligence, industry participants can capture emerging opportunities and deliver impactful outcomes for the growing BPH patient population.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Benign Prostatic Hyperplasia Treatment Market, by Treatment Type

  • 8.1. Medications
    • 8.1.1. 5-Alpha-Reductase Inhibitors
    • 8.1.2. Alpha Blockers
  • 8.2. Minimally Invasive Therapies
    • 8.2.1. Prostate Artery Embolization
    • 8.2.2. Water Vapour Therapy
  • 8.3. Surgical Treatments
    • 8.3.1. Laser Surgery
    • 8.3.2. Prostatic Urethral Lift
    • 8.3.3. Transurethral Incision Of The Prostate
    • 8.3.4. Transurethral Resection Of The Prostate

9. Benign Prostatic Hyperplasia Treatment Market, by Product Type

  • 9.1. Catheters
  • 9.2. Electrodes
  • 9.3. Implants
  • 9.4. Prostatic Stents
  • 9.5. Resectoscopes
  • 9.6. Urology Laser

10. Benign Prostatic Hyperplasia Treatment Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Clinics
  • 10.3. Homecare
  • 10.4. Hospitals

11. Benign Prostatic Hyperplasia Treatment Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Benign Prostatic Hyperplasia Treatment Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Benign Prostatic Hyperplasia Treatment Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Benign Prostatic Hyperplasia Treatment Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Benign Prostatic Hyperplasia Treatment Market

16. China Benign Prostatic Hyperplasia Treatment Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alembic Pharmaceuticals Limited
  • 17.7. Asahi Kasei Corporation
  • 17.8. Astellas Pharma Inc.
  • 17.9. Bayer AG
  • 17.10. Boehringer Ingelheim GmbH
  • 17.11. Boston Scientific Corporation
  • 17.12. Cipla Ltd.
  • 17.13. Coloplast Group
  • 17.14. Dr. Reddy's Laboratories
  • 17.15. Eli Lilly and Company
  • 17.16. Endo International PLC
  • 17.17. GlaxoSmithKline plc
  • 17.18. Hikma Pharmaceuticals PLC
  • 17.19. IPG Photonics Corporation
  • 17.20. Lumenis Ltd.
  • 17.21. Olympus Corporation
  • 17.22. Organon group of companies
  • 17.23. PROCEPT BioRobotics Corporation
  • 17.24. ProstaLund AB
  • 17.25. Quanta System
  • 17.26. Richard Wolf GmbH
  • 17.27. Teleflex Incorporated
  • 17.28. Urologix, LLC.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY 5-ALPHA-REDUCTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ALPHA BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATE ARTERY EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY WATER VAPOUR THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY LASER SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC URETHRAL LIFT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL INCISION OF THE PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TRANSURETHRAL RESECTION OF THE PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ELECTRODES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PROSTATIC STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY RESECTOSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY UROLOGY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY MINIMALLY INVASIVE THERAPIES, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)